[Initial therapeutic trials of an antibilharzial agent, 35 972 R.P. in man].
35,972 R. P. is a new schistosomicidal drug deriving from a thione dithiole pyrazinyl basic structure. It has been assessed with 125 patients suffering from an urinary tract schistosomiasis (69 cases) or from an intestinal schistosomiasis (56 cases). Five regimens have been followed. The last one was 1.50 g/day over 3 days and it included 75 patients. The clinical tolerance was satisfactory although vomiting was reported in 16 % cases and headaches were noted in 21 % cases. The efficiency was remarkable as 97 % patients were cured. New studies are been performed on a one day treatment basis.
D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy; D011719:Pyrazines / Q000627:therapeutic use*; D012548:Schistosoma haematobium; D012550:Schistosoma mansoni; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000627:therapeutic use*; D013871:Thiones; D013876:Thiophenes; D014552:Urinary Tract Infections / Q000188:drug therapy
D011719:Pyrazines; D012556:Schistosomicides; D013871:Thiones; D013876:Thiophenes; C026209:oltipraz
Premiers essais thérapeutiques chez l'homme de l'antibilharzien 35 972 R. P.